Myotonic dystrophy type 1 (DM1) is caused by expansion of CTG repeats in the 3′ UTR of the DMPK gene. Expression of CUG expansion (CUG exp ) RNA produces a toxic gain of function by disrupting the functions of RNA splicing factors, such as MBNL1 and CELF1, leading to splicing changes associated with clinical abnormalities. Progressive skeletal muscle weakness and wasting is one of the most prominent clinical features in DM1; however, the underlying mechanisms remain unclear. Here we report that the embryonic M2 isoform of pyruvate kinase (PKM2), a key enzyme contributing to the Warburg effect in cancer, is significantly induced in DM1 tissue and mouse models owing to aberrant splicing. Expression of PKM2 in DM1 skeletal muscle is restricted to the type 1 fibers, which are particularly susceptible to wasting in DM1. Using antisense oligonucleotides to shift PKM splicing toward increased PKM2 expression, we observed increased glucose consumption with reduced oxidative metabolism in cell culture and increased respiratory exchange ratio in mice, suggesting defects in energy metabolism conferred by PKM2 expression. We propose that PKM2 expression induces changes in type 1 fibers associated with muscle atrophy and muscle weakness in DM1. muscular dystrophy | redirected splicing | striated muscle development | alternative splicing M yotonic dystrophy (DM) is the most common adult-onset form of muscular dystrophy (1, 2). It is caused by expanded CTG repeats in the 3′ UTR of the DMPK gene (type 1; DM1) or expanded CCTG repeats in the first intron of the CNBP gene (type 2; DM2) (3-5). The RNAs transcribed from the expanded CTG or CCTG alleles produce a dominant toxic gain of function (2, 6). The toxicity of CUG-and CCUG-expanded RNAs (CUG exp and CCUG exp RNA) involves two main pathogenic mechanisms. First, CUG exp or CCUG exp RNAs bind and sequester muscleblindlike (MBNL) proteins within ribonuclear foci, resulting in MBNL loss of function (7,8). Second, CUG exp RNA activates protein kinase C, which phosphorylates and stabilizes CELF1, resulting in its elevation and gain of function (9). MBNL and CELF1 proteins regulate alternative splicing during development, and disruption of their functions leads to aberrant splicing transitions implicated in such manifestations of DM as myotonia and insulin resistance (2).Progressive muscle weakness and wasting are among the most prominent clinical features of DM1 (1). In contrast to other forms of muscular dystrophy, such as Duchenne muscular dystrophy, the muscle weakness and wasting in DM1 is not accompanied by overt regeneration, fibrosis and necrosis. Instead, the most prominent histological abnormalities in DM1 are centralized nuclei and slow myofiber (type 1 fiber) atrophy (1). Early studies suggested that reduced protein synthesis and an imbalance of anabolism and catabolism may be responsible for the muscle wasting in DM1 (10, 11). Recent studies have shown that abnormal T-tubule biogenesis and calcium signaling, along with increased glycogen synthase kinase 3β (GSK3β) ...